What Is CagriSema?
CagriSema is a fixed-dose combination therapy developed by Novo Nordisk that combines two active ingredients in a single weekly subcutaneous injection: cagrilintide, a long-acting amylin analog, and semaglutide 2.4 mg, the same GLP-1 receptor agonist used in Wegovy. The idea is straightforward — target two distinct hormonal pathways that regulate appetite and metabolism instead of relying on just one. Novo Nordisk designed CagriSema specifically for chronic weight management in adults with obesity, and it represents the company's answer to Eli Lilly's dual-agonist Zepbound (tirzepatide).
How the Amylin + GLP-1 Dual Mechanism Works
GLP-1 receptor agonists like semaglutide work by mimicking the incretin hormone GLP-1. They slow gastric emptying, reduce appetite through hypothalamic signaling, and improve insulin secretion after meals. This mechanism is well-established and drives the efficacy of Ozempic, Wegovy, and Rybelsus.
Amylin is a different hormone, co-secreted with insulin from pancreatic beta cells after eating. It promotes satiety through a separate set of brainstem and hypothalamic receptors, slows gastric emptying via a distinct mechanism, and suppresses postprandial glucagon. Cagrilintide is a synthetic, long-acting analog of amylin engineered for once-weekly dosing.
By combining both agents, CagriSema activates two parallel satiety pathways — GLP-1-mediated and amylin-mediated — which appears to produce additive weight loss beyond what either drug achieves alone. This is a fundamentally different dual-agonist strategy than tirzepatide's GIP + GLP-1 approach.
REDEFINE Trial Results
The REDEFINE clinical program provides the core efficacy evidence for CagriSema.
REDEFINE-1 was a 68-week, placebo-controlled trial in adults with obesity (BMI ≥30 or ≥27 with comorbidities). Patients on CagriSema achieved a mean weight loss of 22.7% from baseline, compared to roughly 2% with placebo. This placed CagriSema among the most effective anti-obesity medications tested in any pivotal trial to date.
REDEFINE-4 was the head-to-head showdown against tirzepatide (Zepbound). After 72 weeks, CagriSema produced a mean weight loss of 23.0%, while tirzepatide achieved 25.5%. Tirzepatide won the primary endpoint, but the margin was narrower than many analysts expected. CagriSema clearly demonstrated it belongs in the same efficacy tier as tirzepatide, even if it did not surpass it.
FDA Status and Timeline
Novo Nordisk submitted its New Drug Application (NDA) for CagriSema in December 2025. As of April 2026, the FDA has accepted the filing but has not assigned an official PDUFA (Prescription Drug User Fee Act) target date. Industry consensus places the likely decision around October 2026, based on typical FDA review timelines for priority submissions. If approved, CagriSema could reach pharmacies by late 2026 or early 2027.
Estimated Pricing
Novo Nordisk has not announced CagriSema's list price. Based on Wegovy's current wholesale acquisition cost (~$1,350/month) and the premium positioning of a dual-mechanism product, analysts estimate CagriSema will launch at $1,000–$1,300 per month without insurance. Novo Nordisk is expected to offer co-pay savings cards and patient assistance programs similar to those available for Wegovy, potentially bringing out-of-pocket costs to $25–$200/month for commercially insured patients. Whether PBMs and insurers cover CagriSema broadly will depend on formulary negotiations that are still in progress.
Can't wait? Oral GLP-1 options available now — from $99/mo
While CagriSema awaits FDA approval, MEDVi offers oral GLP-1 tablets and injectables today. A provider helps you choose the right option.
See GLP-1 Options Available Now →Side Effects from Clinical Trials
The adverse event profile in the REDEFINE trials was consistent with other GLP-1 therapies, with gastrointestinal symptoms dominating. The most common side effects at maintenance doses included:
- Nausea — reported in roughly 38% of participants, usually mild-to-moderate and improving after weeks 4–8
- Constipation — approximately 24%
- Vomiting — approximately 19%
- Diarrhea — approximately 15%
Discontinuation rates due to adverse events were comparable to other GLP-1 trials. Serious events such as pancreatitis and gallbladder disease were rare and occurred at rates similar to placebo. No new safety signals emerged beyond what is already known for the GLP-1 class.
Who Might Be a Candidate for CagriSema?
If approved, CagriSema is likely to be indicated for adults with a BMI ≥30 kg/m², or ≥27 kg/m² with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea). It may be especially relevant for:
- Patients who have plateaued on single-agent GLP-1 therapy and want more weight loss
- Patients seeking a once-weekly injection who prefer Novo Nordisk's pen platform
- People who want an alternative dual-mechanism approach to tirzepatide's GIP + GLP-1 pathway
CagriSema is not expected to be appropriate for patients with a personal or family history of medullary thyroid carcinoma or MEN2, consistent with existing GLP-1 labeling restrictions.
CagriSema vs. Current Alternatives at a Glance
| Feature | CagriSema | Zepbound (Tirzepatide) | Wegovy (Semaglutide 2.4 mg) |
|---|---|---|---|
| Mechanism | Amylin + GLP-1 | GIP + GLP-1 | GLP-1 only |
| Avg Weight Loss | 22.7% (REDEFINE-1) | ~21% (SURMOUNT-1) | ~15% (STEP 1) |
| Dosing | Weekly injection | Weekly injection | Weekly injection |
| FDA Status | Pending (~Oct 2026) | Approved (Nov 2023) | Approved (Jun 2021) |
| Est. Monthly Cost | $1,000–$1,300 | $1,060 | $1,350 |
| Main GI Side Effects | Nausea, constipation, vomiting | Nausea, diarrhea, constipation | Nausea, diarrhea, vomiting |
What You Can Do Right Now
CagriSema is not available today. If you are considering a GLP-1 for weight management, the options you can start now include Zepbound (tirzepatide), Wegovy or Wegovy HD 7.2 mg (semaglutide), Foundayo (oral orforglipron), and telehealth-prescribed compounded semaglutide or tirzepatide. Waiting six or more months for a drug that may or may not launch on schedule is rarely the right medical decision when proven alternatives are accessible. If CagriSema is ultimately approved and looks right for you, switching at that point is a conversation to have with your prescriber — not a reason to delay treatment today.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication.